Whim Syndrome Pipeline, Clinical Trials, and Key Companies X4 Pharmaceuticals

(United States, Nevada, Las Vegas),DelveInsight's, "WHIM Syndrome - Pipeline Insight, 2023," report provides comprehensive insights about companies and pipeline drugs in WHIM Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download the sample page @ https://www.delveinsight.com/sample-request/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Takeaways from the Whim Syndrome Pipeline Report
Leading Whim Syndrome companies developing novel drug candidates to improve the Whim Syndrome treatment landscape include X4 Pharmaceuticals and many others.
Promising Whim Syndrome pipeline therapies in various stages of development include Mavorixafor (X4P-001) and many others

Whim Syndrome Overview
WHIM Syndrome is a rare primary immunodeficiency disorder, which are disorder in which the body's immune system does not function properly. WHIM is an acronym for some of the characteristic symptoms of the disorder - (w)arts, (h) hypogammaglobulinemia, (i) infections, and (m)yelokathexis. Individuals with WHIM Syndrome are more susceptible to potentially life-threatening bacterial infections. They are also predisposed to viral infections. Affected individuals are particularly susceptible to human papillomavirus (HPV), which can cause skin and genital warts and potentially lead to cancer. Affected individuals have extremely low levels of certain white blood cells (neutrophils) leading to a condition called neutropenia. In most patients, WHIM Syndrome is caused by changes (mutations) in the CXCR4 gene. This mutation is inherited in an autosomal dominant pattern.

Whim Syndrome Pipeline Analysis: Drug Profile
Mavorixafor (X4P-001): X4 Pharmaceuticals
X4 is developing Mavorixafor as a first-in-class, oral, allosteric inhibitor of CXCR4 for the treatment of WHIM Syndrome. WHIM Syndrome is a rare genetic primary immunodeficiency that results from a "gain of function" mutation in the single gene that encodes for the CXCR4 receptor. This genetic mutation causes premature truncations in the CXCR4 protein, causing the receptor to remain in an "on" state longer than normal, resulting in compromised immune cell trafficking and surveillance. X4 has achieved clinical proof of concept for Mavorixafor in WHIM Syndrome where, in the completed Phase 2 trial, X4 observed clinically meaningful increases in neutrophil and lymphocyte counts and a favorable safety profile. Based on the positive Phase 2 results, X4 has initiated the Phase 3 pivotal trial of mavorixafor in WHIM Syndrome.

Discover more about the emerging Whim Syndrome Treatment Drugs @https://www.delveinsight.com/report-store/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Whim Syndrome Pipeline Therapies and Key Companies
Mavorixafor (X4P-001): X4 Pharmaceuticals
And many others
Whim Syndrome Pipeline Therapeutics Assessment
Phases
DelveInsight's Report covers around 33+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II and Phase I/II)
Early-stage products (Phase I/II and Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration

WHIM Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type

Products have been categorized under various Molecule types such as
Small molecules
Natural metabolites
Monoclonal antibodies
Product Type

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Whim Syndrome Pipeline Report
Coverage: Global
Key Whim Syndrome Companies: X4 Pharmaceuticals and many others
Key Whim Syndrome Pipeline Therapies: Mavorixafor (X4P-001) and many others

Find out more about the Whim Syndrome treatment options in development Whim Syndrome Clinical Trials @ https://www.delveinsight.com/report-store/whim-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
1. Whim Syndrome Introduction
2. Whim Syndrome Executive Summary
3. Whim Syndrome Overview
4. Whim Syndrome Pipeline Therapeutics
5. Whim Syndrome Late-Stage Products (Phase III)
6. Whim Syndrome Mid-Stage Products (Phase II)
7. Whim Syndrome Early Stage Products (Phase I/II)
8. Whim Syndrome Preclinical Stage Products
9. Whim Syndrome Discovery Stage Products
10. Whim Syndrome Therapeutic Assessment
11. Whim Syndrome Inactive Products
12. Whim Syndrome Collaborations Assessment- Licensing / Partnering / Funding
13. Whim Syndrome Unmet Needs
14. Whim Syndrome Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Adya Kaul
info@delveinsight.com
+1(919)321-6187

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

This release was published on openPR.